New CEO Will Ready Synta For Commercialization As Ganetespib Begins Phase III In NSCLC
This article was originally published in The Pink Sheet Daily
Sanofi’s North American head of pharmaceuticals will move into the top spot at Synta in September, as the company prepares to transition from a clinical-stage to a commercial company. Lead candidate ganetespib has begun Phase III in advanced NSCLC, with final data expected in 2016.
You may also be interested in...
I-SPY 2 investigators are buoyed by “strong signal” for neratinib in high-risk subgroup in adaptive design study. Investors, however, are underwhelmed by results.
Synta’s Newest Phase II Results Could Reshape Ganetespib’s Pivotal Data, But Some Analysts Remain Skeptical
Synta provided one-year follow up data for its Phase IIb/III trial testing ganetespib in NSCLC, and revealed some protocol changes which it believes will de-risk the Phase III design. Analysts on the third quarter earnings call by and large bought into the story, but some skepticism remains.
With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.